Emergent Biosolutions, Inc.
EBSStock
$7.69+13.85%52W
Market Cap$405.55M
P/E7.71x
Div yield—
Beta2.40
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-52.70%
Price vs S&P 500 (4W)1.21%
VGM Score48.94
Market Capitalization$405.55M
P/E Ratio (Annual)7.71x
Earnings Surprise History
Q1 260.21est. -0.25
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EBSEmergent Biosolutions, Inc. | A | F | C | $7.69 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Emergent BioSolutions develops and manufactures pharmaceutical products and medical countermeasures for public health markets. The company operates three main segments: commercial respiratory products including NARCAN and KLOXXADO nasal sprays; government-contracted medical countermeasures such as anthrax and smallpox vaccines; and bioservices. Revenue is primarily derived from the U.S. market.